HRZN
Horizon Technology Finance Corporation
There isn't enough reported data to score HRZN yet.
MS
Morgan Stanley
MS's fundamentals are strong: revenue grew 16% and earnings per share grew 29%. At 15x earnings, it's trading in line with its usual 14x. Analysts expect earnings growth.
HRZN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| N/A | |
| N/A |
HRZN's revenue is currently healthy, and its profitability is stable. Free cash flow and net leverage aren't meaningful measures for financial services companies like HRZN.
MS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
MS's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like MS.
HRZN PE Valuation
HRZN has no meaningful PE right now: it lost money over the past year.
MS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 11x | $134 | -29% |
| Fair | 14x | $178 | -5.7% |
| Forward | 14x | $189 | — |
| Current | 15x | $189 | — |
| Expensive | 18x | $223 | +18% |
Historical ranges are pointers, not guarantees.
MS's PE is in its fair range at 15x. If earnings grow as analysts expect, today's price would be 14x next year's earnings.
HRZN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Strongly weakening | |
| Limited | |
| Moderate |
Analysts expect HRZN's revenue to grow, but its profitability to weaken.
MS Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
MS has the edge over HRZN on the outlook, with more favorable earnings and profitability expectations.
HRZN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.74 | — |
| Q3 2026 | -$0.65 | +$0.04 |
| Q2 2026 | $0.46 | +$1.51 |
| Q1 2026 | $0.53 | +$0.72 |
| Q4 2025 | -$0.06 | -108% |
| Q3 2025 | -$0.69 | -196% |
| Q2 2025 | -$1.05 | -213% |
| Q1 2023 | $1.36 | +9.7% |
| Q4 2022 | $1.06 | -24% |
HRZN is still losing money, but less than at its worst: $0.65 per share over the past year, against $1.05 at its worst in mid-2025.
MS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.39 | +6.3% |
| Q3 2026 | $12.60 | +29% |
| Q2 2026 | $12.37 | +40% |
| Q1 2026 | $11.04 | +29% |
| Q4 2025 | $10.21 | +28% |
| Q3 2025 | $9.76 | +48% |
| Q2 2025 | $8.84 | +45% |
| Q1 2025 | $8.53 | +55% |
| Q4 2024 | $7.95 | +53% |
MS has the edge over HRZN on earnings quality, reporting a profit while its opponent remains loss making.
HRZN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2022 | $13M | +16% |
| Q1 2022 | $8.3M | -16% |
| Q4 2021 | $7.1M | +19% |
| Q3 2021 | $17.1M | +12099% |
| Q2 2021 | $11.1M | -2.2% |
| Q1 2021 | $10M | +303% |
| Q4 2020 | $6M | -41% |
HRZN has the stronger quarterly revenue trend. Revenue is up 16% for HRZN versus up 12% for MS.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2022 | 60% | -1.3 points |
| Q1 2022 | 43% | -18 points |
| Q4 2021 | 35% | -8.6 points |
| Q3 2021 | 75% | +2397 points |
| Q2 2021 | 61% | -8.6 points |
| Q1 2021 | 61% | +90 points |
| Q4 2020 | 44% | -25 points |
| Q3 2020 | -2321% | N/A |
HRZN's operating margin was 60% last quarter, down 1.3 points from the same quarter a year ago.
MS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $20.3B | +12% |
| Q2 2026 | $21.3B | +27% |
| Q1 2026 | $20.6B | +16% |
| Q4 2025 | $17.9B | +10% |
| Q3 2025 | $18.2B | +18% |
| Q2 2025 | $16.8B | +12% |
| Q1 2025 | $17.7B | +17% |
| Q4 2024 | $16.2B | +26% |
MS's revenue has grown year over year for 14 quarters in a row: $20.3B last quarter, up 12% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 32% | -1.2 points |
| Q2 2026 | 34% | +6.9 points |
| Q1 2026 | 34% | +2.8 points |
| Q4 2025 | 32% | +2 points |
| Q3 2025 | 33% | +5.6 points |
| Q2 2025 | 28% | +0.4 points |
| Q1 2025 | 31% | +2.2 points |
| Q4 2024 | 30% | +14 points |
MS's operating margin was 32% last quarter, down 1.2 points from the same quarter a year ago.
HRZN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.2M | -98% |
| Q2 2026 | $123.5M | +149% |
| Q1 2026 | -$42.1M | -$28.9M |
| Q4 2025 | -$30.4M | -$4.3M |
| Q3 2025 | $50.6M | +$78.9M |
| Q2 2025 | $49.6M | -8.6% |
| Q1 2025 | -$13.2M | -426% |
| Q4 2024 | -$26.1M | -333% |
HRZN has the edge over MS on cash generation, producing positive trailing cash flow while its opponent burns cash.
MS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$46B | -$42.7B |
| Q2 2026 | -$2.7B | -123% |
| Q1 2026 | -$7.1B | +$16.9B |
| Q4 2025 | -$2.4B | -120% |
| Q3 2025 | -$3.3B | +$14B |
| Q2 2025 | $11.8B | +368% |
| Q1 2025 | -$24B | -650% |
| Q4 2024 | $11.8B | +$29.6B |
MS's free cash flow was −$58.3B over the past year, against −$3.7B the year before. Free cash flow isn't a meaningful measure for financial services companies like MS.
HRZN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.1% | +1.3M shares |
| 1 year | +61% | +25.1M shares |
| 3 years | +123% | +36.6M shares |
| 5 years | +234% | +46.5M shares |
| Available history | +347% | +51.5M shares |
HRZN has 66M diluted shares, up 61% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $10M |
| Q2 2022 | — |
| Q1 2022 | — |
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
MS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.2% | -3M shares |
| 1 year | -1.5% | -24M shares |
| 3 years | -4.7% | -77M shares |
| 5 years | -14% | -246M shares |
| Available history | -4.5% | -74M shares |
MS has the edge over HRZN on shareholder dilution, with a more favorable share count trend.
HRZN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2022 | 11.5x | High |
| Q1 2022 | 9.1x | High |
| Q4 2021 | 7.7x | High |
| Q3 2021 | 8.3x | High |
| Q2 2021 | 15.5x | High |
| Q1 2021 | 12.6x | High |
| Q4 2020 | 25.3x | High |
| Q3 2020 | 11.9x | High |
HRZN's net debt is about 12 years of its operating earnings (EBITDA), down from 16 years a year ago. Net leverage isn't a meaningful measure for financial services companies like HRZN.
MS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 7.8x | High |
| Q2 2026 | 7.3x | High |
| Q1 2026 | 8.2x | High |
| Q4 2025 | 8.6x | High |
| Q3 2025 | 8.4x | High |
| Q2 2025 | 8.7x | High |
| Q1 2025 | 8.7x | High |
| Q4 2024 | 7.9x | High |
MS's net debt is about 7.8 years of its operating earnings (EBITDA), down from 8.4 years a year ago. Net leverage isn't a meaningful measure for financial services companies like MS.
HRZN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.5 | Neutral |
| Stochastic | 12.2 | Oversold |
HRZN's weekly RSI is 34 (neutral) and its Stochastic is 12 (oversold).
MS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.0 | Neutral |
| Stochastic | 18.7 | Oversold |
MS's weekly RSI is 45 (neutral) and its Stochastic is 19 (oversold).
HRZN PE vs Financial Services Sector
| Metric | HRZN | Sector median | Relative |
|---|---|---|---|
| PE | 8.9x | 13x | 32% below |
| PE % | 14 | 63 | 49 pts below |
HRZN has the edge over MS on valuation relative to its sector.
MS PE vs Financial Services Sector
| Metric | MS | Sector median | Relative |
|---|---|---|---|
| PE | 15x | 13x | 15% above |
| PE % | 59 | 63 | 4 pts below |
MS is trading at 15x earnings, a 15% premium to the Financial Services sector's median of 13x.
HRZN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.23 | 11% below |
| 20 week MA | $4.51 | 17% below |
| 50 week MA | $4.95 | 24% below |
| 100 week MA | $6.40 | 41% below |
| 200 week MA | $9.08 | 59% below |
HRZN is in a downtrend: it's below all five of its weekly moving averages, and 59% below its 200-week average.
MS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $186.5 | 1.5% above |
| 20 week MA | $203.3 | 6.9% below |
| 50 week MA | $191.9 | 1.4% below |
| 100 week MA | $164.9 | 15% above |
| 200 week MA | $129.3 | 46% above |
MS has the edge over HRZN on trend strength, trading above more of its moving averages.
HRZN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $12.4 | $13.0 | +4.9% |
| 2021 | $13.0 | $15.8 | +22% |
| 2022 | $15.8 | $11.6 | -26% |
| 2023 | $11.6 | $13.2 | +13% |
| 2024 | $13.2 | $9.00 | -32% |
| 2025 | $9.00 | $6.34 | -30% |
| 2026 YTD | $6.34 | $3.76 | -41% |
HRZN has finished lower in three of the last six years. It's down 41% so far in 2026.
MS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $51.1 | $68.1 | +33% |
| 2021 | $68.1 | $99.3 | +46% |
| 2022 | $99.3 | $86.1 | -13% |
| 2023 | $86.1 | $93.3 | +8.3% |
| 2024 | $93.3 | $126.8 | +36% |
| 2025 | $126.8 | $181.9 | +43% |
| 2026 YTD | $181.9 | $189.2 | +4% |
MS has the edge over HRZN on returns for 2026, with the stronger performance.